Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Naltrexone: More than a prayer

With the exception of oral naltrexone, prayer is just about the only treatment for alcoholism. The problem with the drug is that alcoholics tend to be non-compliant patients, and thus don't take the mu-opiod antagonist every day. To get around that problem, Alkermes Inc. and DrugAbuse Sciences Inc. are developing similar long-acting injectable formulations. Both contend that the market is large enough for two.

DrugAbuse appears

Read the full 662 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers